Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 13, pp 4382–4391 | Cite as

Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis

  • Michael N. Mavros
  • Li Xu
  • Hadia Maqsood
  • Faiz Gani
  • Aslam Ejaz
  • Gaya Spolverato
  • Waddah B. Al-Refaie
  • Steven M. Frank
  • Timothy M. PawlikEmail author
Pancreatic Tumors

Abstract

Background

Perioperative blood transfusion (PBT) is common in pancreatic surgery. Recent studies have suggested that PBT may be associated with worse long-term outcomes.

Methods

A systematic review and meta-analysis of studies comparing long-term clinical outcomes of cancer patients undergoing curative-intent pancreatic surgery with regard to occurrence of PBT was performed.

Results

A total of 23 studies (4339 patients) were included in the systematic review, and 19 studies (3646 patients) were included in the meta-analysis. Nearly half (45.8 %) of all patients were female (range 25–60 %), and median age ranged from 59 to 72 years. About half (46.5 %, range 19–72 %) of the patients were transfused. Most had pancreatic ductal adenocarcinoma (69.5 %), while others had ampullary carcinoma (15.0 %), cholangiocarcinoma (7.4 %), or exocrine tumors of pancreas (8.1 %). Most (91.1 %) underwent pancreaticoduodenectomy, while the remaining patients underwent a total or distal pancreatectomy. The 5-year overall survival for all patients ranged from 0 to 65 %. Thirteen and nine of 19 studies reported a detrimental effect of PBT on survival on univariable and multivariable analysis, respectively. Overall, PBT was associated with shorter overall survival (pooled odds ratio 2.43, 95 % confidence interval 1.90–3.10); this finding was reproduced in sensitivity analysis.

Conclusions

Patients receiving PBT had significantly lower 5-year survival after curative-intent pancreatic surgery. Further research should focus on implementing guidelines for and discerning factors associated with the poor outcomes after PBT.

Keywords

Distal Pancreatectomy Pancreatic Ductal Adenocarcinoma Pancreatic Resection Ampullary Carcinoma Transfusion Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

None.

References

  1. 1.
    Ross A, Mohammed S, Vanburen G, Silberfein EJ, Artinyan A, Hodges SE, et al. An assessment of the necessity of transfusion during pancreatoduodenectomy. Surgery. 2013;154:504–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Ejaz A, Spolverato G, Kim Y, Frank SM, Pawlik TM. Variation in triggers and use of perioperative blood transfusion in major gastrointestinal surgery. Br J Surg. 2014;101:1424–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Ejaz A, Spolverato G, Kim Y, Margonis GA, Gupta R, Amini N, et al. Impact of blood transfusions and transfusion practices on long-term outcome following hepatopancreaticobiliary surgery. J Gastrointest Surg. 2015;19:887–96.CrossRefPubMedGoogle Scholar
  4. 4.
    Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012;256:235–44.CrossRefPubMedGoogle Scholar
  5. 5.
    Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;1:CD005033.PubMedGoogle Scholar
  6. 6.
    Sun C, Wang Y, Yao HS, Hu ZQ. Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis. Int J Surg. 2015;13:102–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Amini N, Spolverato G, Kim Y, Pawlik TM. Trends in hospital volume and failure to rescue for pancreatic surgery. J Gastrointest Surg. 2015;19(9):1581–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Ahmad SA, Edwards MJ, Sutton JM, Grewal SS, Hanseman DJ, Maithel SK, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg. 2012;256:529–37.CrossRefPubMedGoogle Scholar
  9. 9.
    Clarke CN, Sussman JJ, Abbott DE, Ahmad SA. Factors affecting readmission after pancreaticoduodenectomy. Adv Surg. 2013;47:99–110.CrossRefPubMedGoogle Scholar
  10. 10.
    Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–5.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Hamidian-Jahromi A, Zibari GB, Jafarimehr E, Chu Q, Wellman GP, Shi R, et al. Peripancreatic soft tissue involvement: independent outcome predictor in patients with resected pancreatic adenocarcinoma. Int Surg. 2014;99:62–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg. 1935;102:763–79.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Clark E, Connor S, Taylor MA, Hendry CL, Madhavan KK, Garden OJ, et al. Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2007;9:472–7.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Rosmarakis ES, Soteriades ES, Vergidis PI, Kasiakou SK, Falagas ME. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J. 2005;19:673–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Wells GA, Shea B, O’Connell D, Peterson JEA, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed May 15, 2015.
  16. 16.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  17. 17.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Dusch N, Weiss C, Strobel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2014;18:674–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J, et al. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2013;15:49–60.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, van Leeuwen DJ, de Wit LT, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75:2069–76.CrossRefPubMedGoogle Scholar
  22. 22.
    Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Mosella G. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital. 2000;52:263–70.PubMedGoogle Scholar
  23. 23.
    Bower MR, Ellis SF, Scoggins CR, McMasters KM, Martin RC. Phase II comparison study of intraoperative autotransfusion for major oncologic procedures. Ann Surg Oncol. 2011;18:166–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Di Giorgio A, Alfieri S, Rotondi F, Prete F, Di Miceli D, Ridolfini MP, et al. Pancreatoduodenectomy for tumors of Vater’s ampulla: report on 94 consecutive patients. World J Surg. 2005;29:513–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim HJ, Sohn TS, Lee KT, Lee JK, Paik SW, Rhee JC. Expression of cyclooxygenase-2 and its correlation with clinicopathologic factors of ampulla of Vater cancer. J Korean Med Sci. 2003;18:218–24.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Kneuertz PJ, Patel SH, Chu CK, Maithel SK, Sarmiento JM, Delman KA, et al. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol. 2011;18:1327–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999;65:618–23.PubMedGoogle Scholar
  28. 28.
    Muller SA, Mehrabi A, Rahbari NN, Warschkow R, Elbers H, Leowardi C, et al. Allogeneic blood transfusion does not affect outcome after curative resection for advanced cholangiocarcinoma. Ann Surg Oncol. 2014;21:155–64.CrossRefPubMedGoogle Scholar
  29. 29.
    Park SJ, Kim SW, Jang JY, Lee KU, Park YH. Intraoperative transfusion: is it a real prognostic factor of periampullary cancer following pancreatoduodenectomy? World J Surg. 2002;26:487–92.CrossRefPubMedGoogle Scholar
  30. 30.
    Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137:396–402.CrossRefPubMedGoogle Scholar
  31. 31.
    Sakamoto Y, Shimada K, Nara S, Esaki M, Ojima H, Sano T, et al. Surgical management of infrahilar/suprapancreatic cholangiocarcinoma: an analysis of the surgical procedures, surgical margins, and survivals of 77 patients. J Gastrointest Surg. 2010;14:335–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83:625–31.CrossRefPubMedGoogle Scholar
  33. 33.
    Sutton JM, Kooby DA, Wilson GC, Squires III MH, Hanseman DJ, Maithel SK, et al. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg. 2014;18:1575–87.CrossRefPubMedGoogle Scholar
  34. 34.
    Takai S, Satoi S, Toyokawa H, Yanagimoto H, Sugimoto N, Tsuji K, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas. 2003;26:243–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Talamini MA, Moesinger RC, Pitt HA, Sohn TA, Hruban RH, Lillemoe KD, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg. 1997;225:590–9.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, et al. Prognostic factors after resection of pancreatic cancer. World J Surg. 2009;33:104–10.CrossRefPubMedGoogle Scholar
  37. 37.
    van Geenen RC, van Gulik TM, Offerhaus GJ, de Wit LT, Busch ORC, Obertop H, et al. Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. Eur J Surg Oncol. 2001;27:549–57.CrossRefPubMedGoogle Scholar
  38. 38.
    Yao HS, Wang Q, Wang WJ, Hu ZQ. Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis. World J Surg. 2008;32:2038–46.CrossRefPubMedGoogle Scholar
  39. 39.
    Yeh JJ, Gonen M, Tomlinson JS, Idrees K, Brennan MF, Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg. 2007;94:466–72.CrossRefPubMedGoogle Scholar
  40. 40.
    Ejaz A, Frank SM, Spolverato G, Kim Y, Pawlik TM. Potential economic impact of using a restrictive transfusion trigger among patients undergoing major abdominal surgery. JAMA Surg. 2015;150:625–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Ejaz A, Spolverato G, Kim Y, Frank SM, Pawlik TM. Identifying variations in blood use based on hemoglobin transfusion trigger and target among hepatopancreaticobiliary surgeons. J Am Coll Surg. 2014;219:217–28.CrossRefPubMedGoogle Scholar
  42. 42.
    Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med. 2014;127:124–31 e123.Google Scholar
  43. 43.
    Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157:49–58.CrossRefPubMedGoogle Scholar
  45. 45.
    American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery), American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. J Am Coll Cardiol. 2006;47:2343–55.Google Scholar
  46. 46.
    Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944–82.CrossRefPubMedGoogle Scholar
  47. 47.
    Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman SA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med. 2009;37:3124–57.CrossRefPubMedGoogle Scholar
  48. 48.
    Carson JL, Carless PA, Hebert PC. Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion. JAMA. 2013;309:83–4.CrossRefPubMedGoogle Scholar
  49. 49.
    Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11–21.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Michael N. Mavros
    • 1
    • 2
    • 3
  • Li Xu
    • 2
    • 4
    • 5
  • Hadia Maqsood
    • 2
  • Faiz Gani
    • 2
  • Aslam Ejaz
    • 6
  • Gaya Spolverato
    • 2
  • Waddah B. Al-Refaie
    • 7
  • Steven M. Frank
    • 8
  • Timothy M. Pawlik
    • 2
    Email author
  1. 1.Department of SurgeryMedStar Washington Hospital CenterWashingtonUSA
  2. 2.Department of SurgeryJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Alfa Institute of Biomedical Sciences, MarousiAthensGreece
  4. 4.Department of Hepatobiliary SurgerySun Yat-sen University Cancer CenterGuangzhouChina
  5. 5.State Key Laboratory of Oncology in Southern ChinaGuangzhouChina
  6. 6.Department of SurgeryUniversity of Illinois Hospital and Health Sciences SystemChicagoUSA
  7. 7.Department of SurgeryMedStar Georgetown University Hospital CenterWashingtonUSA
  8. 8.Department of Anesthesiology and Critical Care MedicineJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations